RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

NWRD06 DNA Plasmid for HCC After Curative Resection.

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteBeijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院BeijingHospital page
  2. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  3. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  4. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  5. Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07324304, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC).

    Inclusion criterion 2

    GPC3 positive confirmed by immunohistochemistry (IHC).

    Inclusion criterion 3

    No residual intrahepatic lesions, no lymph node metastasis, and no extrahepatic metastasis confirmed by imaging within 4 weeks prior to the first dose.

    Inclusion criterion 6

    Surgical margin negative. 8. No Vp4 macrovascular invasion, hepatic vein or inferior vena cava macrovascular invasion of any grade after radical resection; Notes: Patients with Vp1, Vp2, or Vp3 macrovascular invasion confirmed by imaging or pathology are eligible.

    Inclusion criterion 8

  3. Must have undergone curative treatment (surgical resection or local ablation) for HCC within 12 weeks prior to the first NWRD06 administration; The interval between radical resection and the first NWRD06 administration was less than 12 weeks, and the interval between hepatic artery interventional therapy and the first NWRD06 administration was more than 7 days.

    Inclusion criterion 5

    Female subjects of childbearing potential must have a negative serum pregnancy test within 1 week prior to the first dose and must agree to use highly effective contraception from the start of the study treatment until the end of the study. Male subjects must be surgically sterile or must agree to use highly effective contraception during the same period.

    Inclusion criterion 11

    Received any systemic anti-tumor therapy for HCC (including chemotherapy, molecular targeted therapy, bio-immunotherapy) within 28 days prior to screening.

    Exclusion criterion 7

    Continuous systemic corticosteroid therapy (dose equivalent to >10 mg/day prednisone) for more than one week within 28 days prior to screening (excluding hormone replacement therapy and inhaled corticosteroids).

    Exclusion criterion 9

  4. Known history of human immunodeficiency virus (HIV) infection or syphilis.

    Exclusion criterion 13

    History or presence of other malignancies, except for: adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, superficial bladder tumors, ductal carcinoma in situ of the breast, or any other malignancy cured for more than 5 years prior to study entry.

    Exclusion criterion 16

  5. Pregnant or lactating women, or women with a positive pregnancy test.

    Exclusion criterion 20

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07324304, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged between 18 and 65 years (inclusive), regardless of gender.
  • Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC).
  • GPC3 positive confirmed by immunohistochemistry (IHC).
  • Barcelona clinic liver cancer (BCLC) stage A/B or Chinese Hepatocellular carcinoma Stage (CNLC) Ib-IIIa.
  • Must have undergone curative treatment (surgical resection or local ablation) for HCC within 12 weeks prior to the first NWRD06 administration; The interval between radical resection and the first NWRD06 administration was less than 12 weeks, and the interval between hepatic artery interventional therapy and the first NWRD06 administration was more than 7 days.
  • No residual intrahepatic lesions, no lymph node metastasis, and no extrahepatic metastasis confirmed by imaging within 4 weeks prior to the first dose.
  • For patients who underwent radical resection, the following intraoperative criteria must be met: 1) No invasion of adjacent organs, no portal lymph node or distant metastasis.
  • Surgical margin negative. 8. No Vp4 macrovascular invasion, hepatic vein or inferior vena cava macrovascular invasion of any grade after radical resection; Notes: Patients with Vp1, Vp2, or Vp3 macrovascular invasion confirmed by imaging or pathology are eligible.
  • ECOG Performance Status of 0 or 1 within 1 week prior to the first dose. 10. Child-Pugh score A/B (≤7) within 1 week prior to the first dose. 11. Adequate organ function within 1 week prior to the first dose: 1) Blood routine: Hemoglobin (Hb) ≥90 g/L; Platelet count (PLT) ≥75×109/L; 2) Liver: Total bilirubin (TB) ≤3× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN; Plasma albumin ≥30g/L; 3) Coagulation: International Normalized Ratio (INR) ≤2.3. 4) Renal: Serum Creatinine (Scr) ≤1.5 × ULN, OR Creatinine Clearance ≥40 mL/min (if Scr >1.5 × ULN).
  • The expected survival time is more than 6 months; 13. Patients with non-viral primary HCC meet the inclusion criteria. For patients with Hepatitis B virus-related primary HCC(HBV-HCC) or Hepatitis C virus-related primary HCC(HCV-HCC), concurrent antiviral therapy is required.
  • Female subjects of childbearing potential must have a negative serum pregnancy test within 1 week prior to the first dose and must agree to use highly effective contraception from the start of the study treatment until the end of the study. Male subjects must be surgically sterile or must agree to use highly effective contraception during the same period.
  • Have fully understood the study and voluntarily signed the ICF, have good communication with the investigator, and are able to complete all treatments, examinations, and visits stipulated in the study protocol.

Exclusion Criteria:

  • Recurrence or metastasis of HCC prior to the first dose.
  • Has not adequately recovered from toxicities and/or complications of the prior curative procedure.
  • Presence of hepatic encephalopathy.
  • Requires regular renal dialysis.
  • Uncontrolled pleural effusion, pericardial effusion, or clinically significant ascites (defined as ascites not easily controlled by diuretic therapy).
  • History of gastrointestinal bleeding within 28 days prior to screening, or active bleeding, or bleeding tendency.
  • Received any systemic anti-tumor therapy for HCC (including chemotherapy, molecular targeted therapy, bio-immunotherapy) within 28 days prior to screening.
  • Participation in another clinical trial within 28 days prior to screening or still within the observational follow-up period of another trial.
  • Continuous systemic corticosteroid therapy (dose equivalent to >10 mg/day prednisone) for more than one week within 28 days prior to screening (excluding hormone replacement therapy and inhaled corticosteroids).
  • History of immunodeficiency or active autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, etc.).
  • History of allogeneic stem cell, tissue, or solid organ transplantation (including bone marrow transplant).
  • Uncontrolled severe infection (> Grade 2 according to NCI-CTCAE v5.0).
  • Known history of human immunodeficiency virus (HIV) infection or syphilis.
  • Severe dysfunction of other major organs or cardiopulmonary diseases.
  • Epilepsy requiring medication (such as steroids or antiepileptic drugs).
  • History or presence of other malignancies, except for: adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, superficial bladder tumors, ductal carcinoma in situ of the breast, or any other malignancy cured for more than 5 years prior to study entry.
  • Known history of severe allergy, allergic diseases, or allergic constitution.
  • Severe psychiatric disorder.
  • History of drug abuse or alcohol addiction.
  • Pregnant or lactating women, or women with a positive pregnancy test.
  • Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07324304, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07324304, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07324304